Here's What Key Metrics Tell Us About ResMed (RMD) Q4 Earnings

Core Insights - ResMed reported $1.35 billion in revenue for the quarter ended June 2025, marking a year-over-year increase of 10.2% and an EPS of $2.55 compared to $2.08 a year ago, exceeding both revenue and EPS consensus estimates [1] Revenue Performance - U.S., Canada, and Latin America - Devices generated $432.8 million, a 6.6% year-over-year increase, slightly below the average estimate of $435.08 million [4] - U.S., Canada, and Latin America - Masks and other products brought in $359.2 million, an 11.8% year-over-year increase, surpassing the average estimate of $349.01 million [4] - Combined Europe, Asia, and other markets - Total revenue reached $389 million, a 13.1% year-over-year increase, exceeding the estimated $371.49 million [4] - Global revenue for Total Sleep and Breathing Health was $1.18 billion, reflecting a 10.2% year-over-year increase, above the estimated $1.16 billion [4] Stock Performance - ResMed shares have returned +8.4% over the past month, outperforming the Zacks S&P 500 composite's +2.7% change, with a current Zacks Rank of 3 (Hold) indicating potential performance in line with the broader market [3]